Contrarian investors identify three beaten-down sectors with buying opportunities: financials (American Express, KKR, Apollo Global Management, Blue Owl Capital, Robinhood), healthcare (Molina Healthcare, Oscar Health, Hims Hers Health), and software (Microsoft, Oracle, ServiceNow, Figma). They recommend avoiding energy stocks, which have rallied too far on momentum and FOMO despite potential long-term gains.

Figma stock fell 28.1% in March 2026 due to a combination of factors including AI disruption concerns for traditional SaaS products, valuation pressures on growth stocks, and broader market volatility. The company itself remains fundamentally strong with positive cash flow and a solid balance sheet, but investor sentiment remains cautious about its ability to navigate the AI transition.

Figma stock has declined 37% in 2026 amid broad market declines and increased competition from artificial intelligence, despite the company maintaining above-average revenue growth rates. The article examines whether the stock represents an undervalued buying opportunity at current levels.

Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.

Adobe CEO Shantanu Narayen is stepping down after 18 years, causing the stock to drop over 5% despite the company beating Q1 earnings estimates with $6.4B in revenue and strong guidance. The departure comes at a critical time as Adobe faces AI disruption threats and slowing growth, though the stock now trades at a cheap 12x P/E ratio, presenting a potential value opportunity.

The article recommends three discounted growth stocks with potential to double: Oracle, trading at a 60% discount from its 52-week high with a strong $523 billion backlog despite debt concerns; Figma, down 80% from its post-IPO high but showing strong product adoption with 136% net dollar retention; and Zscaler, down 55% since November but maintaining robust 26% revenue growth and approaching profitability.

Software stocks have plunged 24% year-to-date amid AI disruption fears, but some SaaS stocks appear oversold. Figma, down 74% from its peak, shows strong growth with 40% revenue increase and GAAP profitability, plus aggressive AI product development. Axon Enterprise, a law enforcement technology leader, posted 39% revenue growth and is investing heavily in AI tools like Draft One for police reports, forecasting $8 billion revenue by 2028.

Figma stock has recovered after earnings, showing 41% revenue growth and positive free cash flow in 2025, but remains down 80% from its IPO high. While the company has carved a niche in UI design where Adobe has struggled, it still operates at a loss with elevated valuation multiples. The stock is recommended only for risk-tolerant investors willing to add shares gradually.

General Magic, a Toronto-based AI company, announced a $7.2M seed funding round led by Radical Ventures to expand its SMS-based AI agents that automate insurance workflows. The platform reduces inbound calls by 30%, deploys in 3 minutes, and saves teams 250+ hours monthly by handling pre-quote, post-quote, and claims coordination. Early deployments with major insurers have reduced time-to-quote from 30 minutes to under 3 minutes.

Cathie Wood's Ark Invest added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday as all three growth stocks trade significantly below their 2025 highs. Figma showed strong Q4 results with 40% revenue growth and improved margins, while CoreWeave benefits from AI infrastructure demand. Recursion faces headwinds after Nvidia exited its stake, though the company remains a clinical-stage AI-driven biotech play.

Ten large-cap stocks were top performers last week, with First Majestic Silver leading gains at 25.23% following better-than-expected Q4 results. Other notable gainers include Moderna (19.68%) on FDA seasonal flu vaccine review news, Global Payments (19.52%) with strong Q4 earnings and a $2.6B buyback authorization, and Coinbase (11.32%). Companies like Omnicom, Garmin, Figma, and Pan American Silver also reported strong quarterly results and positive guidance.

Figma stock surged 18.39% in extended trading after beating Q4 earnings expectations. The company reported EPS of $0.08 versus $0.07 estimate and revenue of $303.78 million versus $293.15 million estimate. Figma also provided strong 2026 guidance, projecting Q1 revenue of $315-317 million and full-year revenue of $1.37-1.374 billion, both exceeding analyst expectations. The company highlighted strong growth in Figma Make with 70%+ quarter-over-quarter user growth and new AI features.